Introduction
Many common medications – both prescription and over-the-counter – can influence the muscle mass and strength gains achievable through resistance exercise. Some drugs impair or blunt muscle hypertrophy and strength development, while others enhance or exaggerate these gains. These effects can arise via various mechanisms such as hormonal alterations, mitochondrial or metabolic impacts, inflammation modulation, or direct effects on protein synthesis or breakdown. Importantly, the magnitude of impact often depends on whether the drug is used acutely (short-term) or chronically (long-term). In this report, we review major medication classes that affect muscle adaptations, discuss their mechanisms of action, summarize supporting evidence (clinical and preclinical), and distinguish acute versus chronic use effects where relevant. Tables at the end provide a structured summary of each drug class, example drugs, their effects on muscle mass and strength, duration context, and strength of evidence.
Medications That Impair Muscle Gains
Glucocorticoids (Corticosteroids)
Examples: Prednisone, Dexamethasone, Cortisone (often used for asthma, autoimmune diseases, etc.)Glucocorticoids are potent anti-inflammatory and immunosuppressant steroids that unfortunately have a well-known catabolic effect on skeletal muscle. Mechanisms: Glucocorticoids (analogous to the hormone cortisol) alter protein metabolism by decreasing protein synthesis and increasing protein breakdown in muscle. They activate muscle proteolytic systems (like the ubiquitin–proteasome pathway), leading to degradation of contractile proteins. They also inhibit amino acid uptake into muscle and blunt the insulin/IGF-1 anabolic signaling, while increasing muscle expression of atrophy-related genes. Over time this results in muscle atrophy, particularly of fast-twitch (Type II) fibers, and reduced strength. Glucocorticoids can also interfere with muscle satellite cell (stem cell) function, impairing muscle repair and growth.
Evidence: Chronic glucocorticoid use (e.g. prolonged high-dose prednisone therapy) is strongly associated with muscle wasting and weakness – a condition termed steroid myopathy. Clinically, up to 60% of Cushing’s syndrome patients (excess cortisol) present with proximal muscle weakness, underscoring the dramatic impact on muscle tissue. In animal studies, glucocorticoids clearly induce loss of muscle mass and strength, confirming a direct catabolic action. The evidence is strong and well-documented. Duration differences: Short-term or acute corticosteroid use (e.g. a brief taper for allergic reactions) usually has limited effect on muscle size, though very high doses can cause transient weakness in some cases. By contrast, long-term use (weeks to months) leads to progressive muscle protein loss and noticeable weakness. The effects are dose- and duration-dependent – higher doses and longer therapy yield greater muscle atrophy. Encouragingly, resistance exercise has been shown in some studies to mitigate steroid-induced muscle loss, so strength training is often recommended to counteract this side effect (when medically feasible).
Statins (HMG-CoA Reductase Inhibitors)
Examples: Atorvastatin (Lipitor), Simvastatin (Zocor), Rosuvastatin (Crestor) – cholesterol-lowering drugs.Statins are widely prescribed to reduce cholesterol, but they can have unintended effects on muscle health. The most common statin side effect is myalgia (muscle pain), and in rare cases statins can cause serious muscle injury (rhabdomyolysis). Even when overt damage doesn’t occur, statins may blunt muscle gains from exercise via several mechanisms. Mechanisms: Statins block the mevalonate pathway (to lower cholesterol), which also reduces production of coenzyme Q10 (ubiquinone) – an important component of mitochondrial electron transport. CoQ10 depletion in muscle can impair mitochondrial energy production. This may lead to reduced energy availability for muscle recovery and growth, and indeed statin-induced mitochondrial dysfunction is hypothesized to hinder training adaptations. Additionally, there is evidence that statins might interfere with muscle protein synthesis signaling pathways. Statins can also induce mild proximal muscle weakness, possibly by affecting muscle fiber membranes or calcium handling, and may lower endogenous steroid hormones (some studies report lower testosterone in men on statins, which could influence anabolism).
Evidence: The evidence linking statins to impaired muscle adaptation is moderate but growing. A notable study in sedentary overweight adults found that simvastatin (40 mg) significantly blunted the benefits of 12 weeks of aerobic exercise: the statin+exercise group saw almost no improvement in cardiorespiratory fitness (+1.5%) versus a ~10% improvement in the exercise-only group, and importantly, skeletal muscle mitochondrial content (citrate synthase activity) decreased in the statin group even as it increased in the exercise-only group. This suggests statins can impair mitochondrial adaptations to training. Another analysis notes that statins can cause muscle weakness, cramps, and reduce exercise performance in some individuals. Clinically, many patients report difficulty with strenuous exercise when starting a statin, likely due to muscle fatigue or pain. On a molecular level, meta-analyses confirm statins reduce muscle CoQ10 levels, and this slower energy production may slow recovery from strength training. In rare cases, severe muscle damage from statins (rhabdomyolysis) can obviously obliterate any training gains, but such cases are uncommon. Duration differences: Many statin side effects manifest in the first weeks of therapy (muscle aches often appear early but sometimes subside after a few weeks of consistent use). If muscle pain persists, switching to a different statin can help. For those who tolerate statins, long-term use might subtly affect muscle adaptive capacity – for example, an older adult on chronic statin therapy might gain slightly less muscle or strength from a training program than an equivalent person not on statins (some studies have observed smaller strength/endurance gains in statin users, though results are mixed). In summary, statins’ interference with muscle gains is possible but person-specific and generally mild. The evidence is moderate – clear in mechanistic and some clinical studies, but not universally observed.
Selective Serotonin Reuptake Inhibitors (SSRIs)
Examples: Fluoxetine (Prozac), Sertraline (Zoloft), Escitalopram (Lexapro) – antidepressants.SSRIs are commonly used to treat depression and anxiety. While their primary targets are neural serotonin levels, SSRIs have systemic effects that can impact skeletal muscle structure and function, especially with long-term use. Mechanisms: SSRIs have been linked to altered muscle metabolism and growth signals. Chronic SSRI exposure is associated with insulin resistance and impaired glucose handling in muscle. This means muscles may take up less glucose, potentially reducing energy available for workouts and recovery. SSRIs can also affect muscle by altering calcium handling and neuromuscular function – some patients on SSRIs report muscle stiffness or tremors (likely from increased serotonin at spinal reflex pathways). Preclinical studies indicate SSRIs may directly influence muscle cells: in rodents, SSRI treatment changed muscle fiber size and number – with reports of decreased muscle fiber cross-sectional area and muscle weight in some cases. The drugs also modified key enzymes and signaling proteins: chronic SSRI use led to changes in muscle glycogen synthase activity, mitochondrial enzyme (citrate synthase) levels, and Akt (protein kinase B) phosphorylation, suggesting disruptions in normal anabolic signaling and energy metabolism. Serotonin itself can affect muscle via receptors in muscle tissue, though this is still being elucidated.
Evidence: There is limited but emerging evidence of SSRIs’ impact on muscle mass and strength. Human data are mostly indirect. For example, elderly adults on SSRIs have been observed to have poorer physical function – one study found SSRI users had lower grip strength and slower walking speed than non-users, hinting at an effect on muscle performance (though depression itself or less physical activity could confound this). The most direct evidence comes from the systematic review of SSRIs’ effects on skeletal muscle: it concluded that SSRIs indeed affect muscle electrical activity, structural properties, and metabolism. Rodent experiments within that review showed reductions in muscle fiber size after SSRI exposure. Additionally, SSRIs may reduce circulating testosterone in men and dampen growth hormone release (since serotonin influences the hypothalamus-pituitary axis), which could indirectly limit muscle-building potential during resistance training. Clinically, some patients on SSRIs report difficulty gaining strength or muscle despite training, though this is anecdotal. Duration differences: Acute SSRI use (days to a couple of weeks) usually causes transient side effects like fatigue, which might make workouts feel harder, but no immediate structural muscle changes. Chronic use (months to years) is where muscular effects manifest – subtle changes in body composition (some SSRI users gain weight, often fat, but potentially lose some lean mass), reduced exercise tolerance, or slower strength progression. The risk might be higher in older adults (where SSRIs could contribute to sarcopenia). Overall, the evidence is limited and not as robust as for other classes, but there is enough concern to warrant further research. Individuals on SSRIs should pay attention to diet and exercise, as well-managed training can likely overcome most negative effects.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Examples: Ibuprofen (Advil/Motrin), Naproxen (Aleve), Aspirin – common OTC pain relievers and anti-inflammatories.NSAIDs are frequently used by athletes and lifters to manage post-workout soreness or injuries. They provide relief by inhibiting cyclooxygenase (COX) enzymes and reducing inflammation. However, inflammation is a double-edged sword in muscle adaptation: a certain amount of acute inflammation is integral to muscle repair and hypertrophy signaling. Mechanisms: NSAIDs (especially at high doses) block COX-1 and COX-2 enzymes, preventing the formation of prostaglandins like PGE_2 and PGF_2α. These prostaglandins are normally elevated after resistance exercise and play a role in stimulating muscle protein synthesis and satellite cell activity (muscle regeneration) as part of the adaptation process. By shutting down this pathway, NSAIDs can blunt the molecular signals that drive muscle growth. NSAIDs also reduce muscle inflammation and pain, which might acutely allow one to train through discomfort, but chronically this anti-inflammatory effect appears to compromise muscle gains. There is also evidence that NSAIDs may attenuate the increase in muscle blood flow after exercise and reduce the activation of anabolic pathways like mTOR, further dampening hypertrophy.
Evidence: A landmark randomized trial tested this directly: Young adults undertaking an 8-week resistance training program were given either high-dose ibuprofen (1200 mg daily, an over-the-counter maximal dose) or a very low dose of aspirin (75 mg daily) as a control. Despite identical training, the ibuprofen group gained significantly less muscle size and strength than the control group. Specifically, quadriceps muscle volume increased by only ~3.7% in the ibuprofen users vs ~7.5% in the low-dose aspirin group, and strength gains (especially from high-intensity eccentric training) were attenuated with ibuprofen. The authors concluded that maximal OTC doses of ibuprofen impair hypertrophic and strength adaptations in young, healthy individuals. Supporting this, a 2017 study (Karolinska Institute) reported that daily ibuprofen (1200 mg) halved the increase in muscle mass in young adults compared to placebo over 8 weeks. Mechanistic studies show NSAIDs prevent the normal post-exercise rise in prostaglandins and muscle satellite cell activity. That said, not all studies agree – some research in older adults paradoxically found that NSAIDs did not significantly blunt gains, and in certain contexts (older individuals with high baseline inflammation or joint pain) NSAIDs might even enable better training by reducing pain. The discrepancy likely relates to age and inflammatory milieu: younger muscle may require the inflammatory response for growth, whereas older muscle’s chronic inflammation is more detrimental. Duration differences: Occasional or short-term NSAID use (e.g. taking ibuprofen only for a day or two after an especially tough workout) is unlikely to have a major effect on long-term muscle gains – the acute blunting of protein synthesis is relatively small and your body can still adapt in subsequent sessions. The concern is more with chronic high-dose use: regularly taking NSAIDs every day or before every workout for weeks to months. Under those conditions, the cumulative dampening of muscle repair signals can measurably hinder hypertrophy and strength improvements, especially in young individuals. In summary, the evidence that NSAIDs (at high dosages) interfere with muscle growth is strong in young populations (multiple RCTs), whereas effects in other populations are still being studied. The prudent advice is to avoid routine high-dose NSAID use if maximal muscle gains are a goal, reserving these drugs for genuine injury or occasional pain management.
Beta-Blockers
Examples: Propranolol (Inderal) – nonselective; Metoprolol (Lopressor) and Atenolol – beta-1 selective; used for high blood pressure, heart conditions, anxiety.Beta-blockers reduce the effects of adrenaline (epinephrine and norepinephrine) by blocking β-adrenergic receptors in the heart and other tissues. They are well known to reduce exercise capacity, particularly endurance/aerobic performance, but they can also indirectly affect strength training outcomes. Mechanisms: By blocking β₁ receptors in the heart, beta-blockers limit the increase in heart rate and cardiac output during exercise. This means during workouts, especially intense sets or high-volume training, muscles may receive less blood flow and oxygen (since cardiac output is blunted). Additionally, nonselective beta-blockers also block β₂ receptors in skeletal muscle and blood vessels. β₂ receptors in muscle normally mediate vasodilation and also have anabolic signals (β₂ stimulation can enhance muscle glycogen uptake and protein synthesis to a degree). Blocking them could reduce muscle glycogen utilization and blunt some exercise-induced anabolic signaling. Another factor is that beta-blockers often cause fatigue, weakness, and lowered motivation as side effects, potentially due to reduced circulation and also possibly due to mild CoQ10 depletion (some beta-blockers, like propranolol, have been noted to deplete coenzyme Q10 similar to statins). This nutrient effect could contribute to muscle fatigue. Lastly, chronic beta blockade might shift muscle fiber type distribution toward more oxidative fibers (since the muscle is continually working under lower intensity conditions), but evidence on fiber shift is limited.
Evidence: For aerobic exercise, the effect of beta-blockers is clearly documented: they can reduce maximal aerobic capacity (VO₂max) by ~10–15% and make exercise subjectively harder at any given workload. For resistance exercise, the evidence is less abundant, but practical experience and some studies indicate that beta-blockers may impair the ability to perform high-intensity work. For instance, a lifter on a beta-blocker might find they reach exhaustion sooner or cannot perform as many repetitions at a heavy load due to early fatigue. One study from the 1980s noted reduced muscular endurance and a lower maximal workload in subjects on beta-blockers during strength testing (likely due to decreased blood supply and blunted adrenaline response). Moreover, beta-blocked individuals might experience less of the adrenaline “rush” that can acutely increase strength output. A Harvard Health article noted that perceived exertion is higher on beta-blockers – in other words, everything feels more strenuous, which can limit how hard an individual trains. Over time, this could translate to smaller strength and hypertrophy gains simply because the person cannot consistently lift as heavy or do as much volume while on the medication. On the other hand, beta-blockers do not directly catabolize muscle or inhibit protein synthesis; any effect on muscle mass is more indirect. Duration differences: The effect of beta-blockers is essentially present acutely every time one exercises while on the drug. A single dose will reduce your heart rate and exercise capacity that day. With chronic use, the body partially adapts (resting fitness might improve a bit with training even on beta-blockers, and perceived exertion might normalize somewhat), but the ceiling on performance remains. Thus, long-term, someone on beta-blockers may find their overall fitness and strength improve with training, but likely not to the same extent as if they were off the medication. The evidence for impact on pure muscle hypertrophy is moderate to limited – there isn’t as much direct research on muscle size – but logically, anything that curtails training intensity can limit hypertrophic stimulus. In summary, beta-blockers constrain how hard you can push your workouts, which can translate to slightly reduced muscle and strength gains over the long haul. This effect is more significant for endurance/cardio performance, but strength athletes should also be aware of it.
Metformin (Biguanide Antidiabetic)
Example: Metformin – first-line oral medication for type 2 diabetes (also studied in prediabetes and anti-aging contexts).Metformin improves insulin sensitivity and lowers blood glucose, primarily by activating the cellular energy sensor AMPK and reducing liver glucose production. Interestingly, these same actions can intersect with pathways of muscle adaptation. Mechanisms: Metformin activates AMPK (AMP-activated protein kinase) in muscle; AMPK is essentially a cellular energy gauge that, when turned on, promotes catabolic processes and inhibits anabolic processes. Chronic AMPK activation can antagonize mTOR signaling – and mTOR is a key driver of muscle protein synthesis. Thus, metformin might impair muscle hypertrophy by blunting mTOR-mediated protein synthesis in response to resistance exercise. Additionally, metformin can dampen inflammation (it’s been observed to lower some inflammatory markers), which in theory might reduce the exercise-induced inflammatory stimuli for muscle growth (somewhat akin to NSAIDs, though via a different mechanism). There’s also an effect on muscle mitochondria: metformin mildly inhibits mitochondrial complex I, which could reduce ATP availability during high-demand situations like intense exercise, potentially limiting training performance or adaptation. On the flip side, by improving insulin sensitivity, metformin helps muscle effectively uptake nutrients – but in non-diabetics, this benefit may be marginal.
Evidence: Recent clinical trials have directly examined metformin’s effect on exercise training in older adults. In the MASTERS trial, healthy seniors (65+ years) did 14 weeks of progressive resistance training; half took metformin (1700 mg/day) and half took placebo. The results showed that metformin significantly blunted muscle hypertrophy compared to placebo. Both groups got stronger and gained some muscle, but the placebo group had greater increases in lean body mass and thigh muscle cross-sectional area. Specifically, gains in thigh muscle mass were higher in the placebo group, and the metformin group had roughly a 50% smaller increase in total lean mass. There was also a trend toward smaller strength gains in the metformin group (not statistically significant, but numerically less). Muscle biopsies from that study indicated that metformin prevented some of the usual anabolic signaling: metformin users showed increased AMPK activity and attenuated mTORC1 activation post-exercise, consistent with the mechanistic expectations. Another trial in older adults with obesity found a similar pattern – metformin users gained less muscle from exercise training than non-users. These findings suggest metformin, despite its health benefits for metabolism, can be counterproductive for muscle building in an older population. It is less clear if young individuals experience the same interference – ongoing studies are examining if metformin might actually improve exercise outcomes in very insulin-resistant individuals or athletes (some had hypothesized it could reduce inflammation and thus aid recovery). But the current evidence leans toward a negative effect on muscle hypertrophy in people without diabetes. Duration differences: Metformin’s effect on muscle gains appears with chronic use over weeks to months; a single dose of metformin before a workout is unlikely to dramatically alter that session’s muscle protein synthesis (though acute effects on AMPK occur). It’s the cumulative influence of taking metformin daily throughout a training program that leads to measurably smaller gains. For someone who needs metformin for medical reasons (e.g. diabetic older adult), this trade-off might be acceptable, but it’s important to recognize. The evidence is strong-moderate in older adults (multiple randomized trials). In younger populations, direct evidence is limited, but given the clear biological pathway (AMPK vs mTOR), many experts suspect similar effects.
Other Medications and Factors
In addition to the major classes above, a few other medications deserve mention for their potential to hinder muscle mass/strength gains:- Chronic Opioid Analgesics (Narcotic pain relievers): Drugs like oxycodone, morphine, or long-acting opioids can indirectly cause muscle loss. They induce a state of hypogonadism by suppressing the body's production of sex hormones (testosterone in men, estrogen in women). Studies show ongoing opioid therapy often leads to low testosterone levels, which in men is associated with reduced muscle mass and strength. Opioids also cause sedation and decreased physical activity; someone on high-dose opioids might simply be too drowsy or unmotivated to train hard. And because opioids block pain, an individual could overexert or injure muscles without normal pain feedback. Acute opioid use (e.g. post-surgery) will transiently weaken physical performance and should be used sparingly in training contexts, whereas chronic use leads to hormonal deficiencies and muscle deconditioning over time. The evidence linking opioids to muscle weakness is considered moderate (well-known endocrine effects, plus observations of improved muscle function when opioid-induced testosterone deficiency is treated).
- Sedatives and Muscle Relaxants: Long-acting benzodiazepines or sleep medications (e.g. zolpidem extended-release) can cause next-day grogginess and poor coordination, which doesn’t directly reduce muscle protein synthesis but impairs the quality of training. If you cannot perform exercises with intensity and good form due to drowsiness, gains will suffer. Similarly, skeletal muscle relaxants (like cyclobenzaprine or carisoprodol) and even first-generation antihistamines (like diphenhydramine found in some OTC sleep aids) cause fatigue and reduced alertness, indirectly hampering workouts. These are short-term effects (while the drug is active in your system). The solution is usually to time workouts for when you’re most alert, or use non-sedating alternatives if possible. Evidence here is limited but straightforward – it’s difficult to gain strength if you’re consistently exercising under the influence of sedatives.
- Fluoroquinolone Antibiotics: A special mention – drugs like ciprofloxacin and levofloxacin are powerful antibiotics that carry a known risk of tendinitis and tendon ruptures, and they can also cause muscle/joint pains. They don’t directly affect muscle growth pathways, but someone on a fluoroquinolone should avoid strenuous resistance exercise to prevent injury. These are usually short-term courses, and any negative effect is more about injury risk than true interference with hypertrophy. However, a ruptured tendon from these drugs will definitely set your strength gains back, so caution is warranted.
- Excess Thyroid Hormone: Thyroid hormone (T3/T4) affects muscle metabolic rate. Hyperthyroidism (or excessive dosing of thyroid meds) causes muscle protein breakdown and can lead to muscle weakness and atrophy (thyrotoxic myopathy). In athletes, some have misused thyroid hormone for weight loss, but an undesired effect is loss of muscle mass along with fat. Conversely, treating hypothyroidism (low thyroid) can improve muscle function if that was impaired. So, thyroid medication impact depends on dose – over-replacement will erode muscle, normalizing levels can aid muscle function. Evidence: strong for hyperthyroid-induced muscle loss (clinical observation), limited in the context of affecting training gains unless dosing is incorrect.
- Androgen Deprivation or Aromatase Inhibitors: In certain medical conditions (prostate cancer treatment with GnRH agonists or androgen blockers, and breast cancer treatment with aromatase inhibitors that lower estrogen), patients experience accelerated muscle loss and weakness. These drugs aren’t commonly encountered by healthy lifters, but they underscore the importance of sex hormones in muscle maintenance. An extreme example is androgen deprivation therapy – within months, men can lose significant lean body mass and muscle strength due to the elimination of testosterone’s anabolic effects. While not a focus of this report, the evidence is strong that loss of anabolic hormones leads to muscle loss.
Having covered the drugs that interfere with muscle building, we will now turn to those that enhance or augment muscle mass and strength gains.
Medications That Enhance Muscle Gains
Anabolic Androgenic Steroids (AAS)
Examples: Testosterone (and esters like Testosterone Enanthate or Cypionate), Dianabol (Methandrostenolone), Trenbolone, Oxandrolone (Anavar). (Note: AAS are prescription-only for certain medical conditions like hypogonadism or muscle wasting, but are frequently abused in sports for performance enhancement.)Anabolic steroids are synthetic derivatives of testosterone or related hormones that powerfully stimulate muscle growth and improve strength. They are arguably the most potent pharmacological means of enhancing muscle mass beyond natural limits. Mechanisms: AAS bind to the androgen receptor in muscle cells, activating genetic programs that increase protein synthesis and decrease protein breakdown. They upregulate the production of muscle proteins (such as myosin and actin), and they also increase the number of muscle cell nuclei (by stimulating satellite cells to fuse with muscle fibers). This provides a greater capacity for growth. Steroids also antagonize the catabolic effects of cortisol, tipping the balance strongly toward anabolism. Additionally, androgens can increase levels of insulin-like growth factor 1 (IGF-1) in muscle and enhance neuromuscular function (users often report improved muscle “activation” or neural drive). There’s even a psychological component: AAS often increase aggression or motivation in training, allowing users to push harder. All these factors contribute to dramatically increased muscle hypertrophy and strength when combined with resistance exercise.
Evidence: The effects of anabolic steroids on muscle size and strength are robustly documented. Classic clinical studies have demonstrated that even without exercise, supraphysiologic doses of testosterone cause significant increases in fat-free mass. With exercise, the gains are even larger. For instance, a famous 1996 New England Journal of Medicine study showed that young men given high-dose testosterone (600 mg/week of testosterone enanthate) gained far more muscle size and strength over 10 weeks than those training without drugs, and even those on testosterone with no exercise gained some muscle mass. It’s not uncommon for a steroid-using lifter to gain several kilograms of lean mass in a matter of 2–3 months, changes that would normally take years naturally. Research on long-term illicit AAS users (e.g. bodybuilders) finds dose-dependent increases in muscle mass: in one study, powerlifters who had used steroids for years had larger muscle fiber cross-sectional areas and higher lean body mass than non-users, and the differences correlated with their cumulative steroid dose. Notably, a 2014 study of strength athletes found long-term AAS use led to significant increases in lean leg mass, muscle fiber size, and a parallel improvement in maximal strength – all in a dose-dependent manner. The “dose-dependent” aspect means higher doses or stacking multiple steroids yields greater gains (but also more risks). Strength gains from steroids are equally impressive: AAS increase one-rep max strength by enhancing muscle mass and also by allowing more intense training. In the aforementioned studies, steroid users’ strength (in exercises like squat or bench press) improved significantly more than non-users’. For example, the long-term user study noted higher absolute squat strength in AAS users (though interestingly, when normalized to muscle size, their “muscle quality” could be slightly lower – likely because they carry some non-contractile mass too). Overall, the evidence is overwhelming that anabolic steroids confer large enhancements in muscle mass and strength beyond natural training. Duration differences: Short-term cycles (e.g. 6–12 weeks) of high-dose AAS already produce dramatic results – athletes can gain 5–20+ pounds of lean mass and see major strength increases in that span. Continuous or long-term use (multiple cycles over years or staying on smaller doses chronically) allows users to maintain and build on those gains, often reaching muscularity that is not otherwise attainable. However, prolonged use also leads to tolerance (diminished returns unless doses are increased) and significant health risks (e.g. liver strain, cardiovascular disease, endocrine shutdown). It’s also notable that some muscle gains from steroids persist long after discontinuation (possibly due to retained extra nuclei in muscle fibers). In summary, AAS have strong, unequivocal evidence for enhancing muscle mass and strength – that’s precisely why they’re banned in sports. Medical use of AAS (like therapeutic testosterone for deficient patients) can also increase muscle mass moderately within the physiological range, improving strength and physical function in older men or those with muscle-wasting diseases.
Beta-2 Adrenergic Agonists
Examples: Clenbuterol (not FDA-approved for human use, but used illicitly), Albuterol/Salbutamol (Ventolin) – an asthma bronchodilator sometimes used at higher doses, Formoterol, Terbutaline.Beta-2 agonists are drugs that activate β₂-adrenergic receptors. In the lungs this causes bronchodilation (hence their use in asthma). In skeletal muscle, β₂ receptors activation has anabolic and anti-catabolic effects. Some beta-2 agonists, especially Clenbuterol, have been used as performance-enhancing drugs for their ability to increase lean muscle mass and reduce body fat. Mechanisms: Beta-2 agonists stimulate the cAMP-PKA pathway in muscle cells. This leads to changes in gene expression that favor muscle hypertrophy – for example, increasing protein synthesis and suppressing ubiquitin-proteasome protein degradation. β₂ stimulation can also induce a shift toward fast-twitch fiber characteristics and enhance muscle force production (though sometimes at the cost of endurance). Clenbuterol in animal models increases muscle mass by enlarging muscle fibers (hypertrophy) and in some cases even causing hyperplasia (formation of new fibers), although hyperplasia in adult humans is not well documented. Additionally, these drugs increase overall metabolism and lipolysis, which reduces fat mass and can make muscles appear more defined. It’s important to note that standard therapeutic doses of inhaled beta-2 agonists (like those for asthma) are too low to have significant anabolic effects – the muscle-building effects come at higher systemic doses, which is why it’s seen in doping.
Evidence: The anabolic impact of beta-2 agonists is well-demonstrated in animal studies – rats or livestock given clenbuterol show marked muscle growth. In humans, data is more limited (due to ethical issues of studying a dangerous drug), but case reports and small studies exist. A randomized controlled trial in patients with chronic heart failure tested Clenbuterol (a potent beta-2 agonist) versus placebo: over several months, the clenbuterol group experienced a significant increase in lean muscle mass and improved muscle strength (leg press strength rose by 27% with clenbuterol vs 14% in placebo). However, their muscle endurance and overall exercise capacity actually decreased on clenbuterol. This illustrates a key point: clenbuterol added muscle size and some strength, but it impaired endurance (likely due to its cardiovascular strain and perhaps a disproportionate fast-twitch fiber shift). The authors noted clenbuterol improved the lean mass to fat ratio considerably. Prior evidence (and doping cases) support that beta-2 agonists increase muscle mass – for instance, in the livestock industry, clenbuterol and similar drugs have been used illegally to produce more muscular cattle (hence the term “cattle steroid”). Another human study found low-dose formoterol (a β₂ agonist) increased muscle mass and strength in patients with chronic disease, suggesting even selective β₂ activation can be beneficial. That said, clenbuterol’s muscle gains may come with a cost: a commentary on the heart failure trial warned that clenbuterol may impair muscle quality and is potentially dangerous, as the added mass may not all be functional contractile tissue. In practical terms, athletes who used clenbuterol often reported muscle cramps and tremors, and if overused, it can cause cardiac hypertrophy (enlargement of the heart) and arrhythmias. Duration differences: Beta-2 agonists can act fairly quickly. Short-term use of clenbuterol (weeks) can yield noticeable muscle gains and fat loss. However, the body also develops tolerance to beta agonists – receptors down-regulate – so the anabolic effect may plateau with continuous use beyond a few weeks. For this reason, users often cycle clenbuterol (e.g. 2 weeks on, 2 weeks off). Long-term continuous use can lead to diminished returns and more side effects, including potential cardiac muscle damage. Some data suggest prolonged high-dose β₂ agonist use can weaken absolute muscle force (perhaps from alterations in calcium handling). Overall, the evidence for muscle growth is moderate to strong (strong in animals, moderate in controlled human studies due to fewer trials). Beta-2 agonists are recognized by sports doping authorities as anabolic agents and are mostly banned, reinforcing their known efficacy in enhancing lean mass.
Human Growth Hormone (hGH)
Example: Somatropin (recombinant human GH) – used for growth hormone deficiency, and abused in sports for muscle/anti-aging claims.Growth hormone is an anabolic peptide hormone that stimulates growth, cell reproduction, and regeneration. Endogenously, it helps children grow taller and in adults it helps regulate body composition. In the context of muscle, GH has some anabolic actions, though not as potent as anabolic steroids. Mechanisms: GH acts both directly and indirectly. It directly binds to GH receptors on muscle, which can enhance amino acid uptake and stimulate protein synthesis. Indirectly, GH causes the liver and local tissues to produce IGF-1 (Insulin-like Growth Factor 1), a powerful growth factor that promotes muscle cell growth and differentiation. GH also increases fat breakdown, providing additional fuel that might spare muscle protein. Another effect of GH is to increase connective tissue and water retention; it can make muscles look “fuller” by increasing intracellular water and promoting collagen synthesis in muscle and tendons. Unlike steroids, GH does not strongly increase muscle strength per unit size – some research suggests GH-induced weight gain is partly due to fluid and not purely contractile protein. GH can also interfere with insulin (causing insulin resistance), which might counteract some muscle benefits in the long run.
Evidence: The effects of GH on muscle mass and performance are mixed. In GH-deficient individuals, GH replacement clearly increases muscle mass, reduces body fat, and improves exercise capacity and strength. For example, adults with GH deficiency experience increased muscle size and better exercise tolerance when given GH injections. However, in healthy individuals, the benefits are less clear-cut. A comprehensive review of 44 studies on GH in athletes found that short-term GH administration (around 3 weeks) led to an average increase of about 2–2.5 kg (~4.6 lbs) in lean body mass, which is significant. But importantly, this gain in lean mass did not translate into greater strength or athletic performance. In the study, measures of muscle strength and power did not improve with GH relative to placebo, and in some cases, athletes on GH felt more fatigued or retained fluid. The lean mass increase was likely due to water retention and perhaps some connective tissue growth, rather than new contractile muscle proteins. Some other studies have noted slight increases in muscle strength of lower body after GH therapy, but these were often in GH-deficient or older populations. A molecular endocrinology perspective noted that GH can increase muscle mass (and thus strength to some extent) without changing muscle fiber type or intrinsic force, implying GH adds quantity but not quality of muscle. In older adults, GH (and IGF-1) have been investigated as treatments for sarcopenia. Trials show modest improvements in body composition (more lean mass, less fat) but again no major gains in functional strength, and side effects like edema, joint pain, and carpal tunnel syndrome are common. Duration differences: Short-term GH use (weeks) can cause rapid weight (lean mass) gain, mostly from fluid shifts and some muscle protein accrual. It doesn’t drastically improve strength in that time. Long-term use (months to years) might lead to some actual muscle fiber hypertrophy and strength increases, especially if combined with resistance training and/or anabolic steroids (some athletes use GH as an “adjunct” to steroids, believing the combination yields extreme growth). Chronic high-dose GH, however, also causes acromegaly-like effects (organ growth, joint problems, diabetes risk). The evidence for GH as a muscle-builder in healthy adults is moderate: it certainly changes body composition, but the functional benefits are limited. It’s considered an ergogenic aid with mixed outcomes. In the medical sphere, GH is approved for muscle wasting in HIV/AIDS and short bowel syndrome because it can help attenuate muscle loss in those conditions – again indicating it does have anabolic potential. Overall, GH can enhance muscle mass modestly but is not nearly as effective as anabolic steroids for strength gains.
Selective Androgen Receptor Modulators (SARMs)
Examples: Ostarine (Enobosarm, GTx-024), LGD-4033 (Ligandrol), RAD-140 (Testolone). (None are yet approved for general use; some are in trials for muscle wasting conditions, and they are encountered on the black market for bodybuilding.)SARMs are a newer class of molecules designed to act like anabolic steroids selectively – aiming to stimulate androgen receptors in muscle and bone, but not in other tissues (to avoid side effects like prostate growth or hair loss). They are essentially experimental muscle-building drugs. Mechanisms: SARMs bind to the androgen receptor similarly to testosterone, but their chemical structure allows them to be more selective in which genes they turn on. They promote protein synthesis and muscle differentiation while supposedly having less impact on prostate or cardiovascular system. Each SARM is different, but generally they cause increased nitrogen retention in muscle and anabolism. They do suppress natural testosterone to some degree (because of hypothalamic feedback), though perhaps less drastically than traditional steroids. SARMs do not aromatize to estrogen, which avoids estrogen-related side effects, but also means they don’t benefit from estrogen’s positive effects on bone and maybe muscle to some extent.
Evidence: Because SARMs are still investigational, most evidence comes from clinical trials for conditions like cancer cachexia or age-related muscle loss. One of the most studied is Ostarine (Enobosarm). In a Phase II trial in healthy older adults (elderly men and postmenopausal women), Ostarine given for 3 months led to a dose-dependent increase in lean body mass – at the highest dose (3 mg daily) they gained about 1.3 kg of lean mass on average compared to placebo. This was accompanied by improvements in physical function tests (like stair climb speed). Another SARM, LGD-4033, was tested in young men: even 21 days of treatment at various doses resulted in dose-dependent increases in lean mass (up to ~1.0 kg at 1 mg/day in 3 weeks) with no significant side effects, demonstrating potent anabolic activity. In terms of strength, the gains reported in short trials are modest but positive. For instance, in the Ostarine trial, there were improvements in power and strength measures, but not as dramatic as one might see with traditional steroids. SARMs generally are less potent than AAS milligram-for-milligram, but they still clearly enhance muscle growth above placebo. Anecdotally, recreational users of SARMs report noticeable increases in muscle fullness and strength over 6–8 week cycles, though usually less than those obtained with steroids (and the long-term safety is unknown). Duration differences: Short-term trial results (weeks to a few months) show measurable increases in muscle mass and slight strength improvement from SARMs. If used longer term, presumably gains would continue, though there may be a ceiling or side effects emerging (like suppression of natural hormones). SARMs are touted to have fewer side effects, but extended use has shown decreases in HDL cholesterol and some liver enzyme elevations in trials. Because they are not fully approved, we lack long-term data. Current evidence is moderate – there are well-conducted trials demonstrating genuine anabolic effects in humans. As more research and perhaps approvals occur, SARMs could become medically useful for muscle wasting diseases, and they are already a concern for anti-doping agencies given their performance-enhancing potential.
Other Agents and Hormones Enhancing Muscle
A few other medications and hormone therapies can affect muscle gains:- Insulin: Although primarily a blood-sugar lowering hormone, insulin is highly anabolic in muscle. It stimulates amino acid uptake and prevents protein breakdown. Diabetics with insulin deficiency suffer muscle loss until insulin therapy is started. Some bodybuilders abuse insulin in combination with high carbohydrate/protein diets to drive nutrients into muscle and boost growth. This is very dangerous due to hypoglycemia risk, but it does increase muscle girth (often along with fat). Insulin’s effect is acute – it’s most relevant post-workout to promote glycogen and protein synthesis. It’s not typically used specifically to increase strength, but more to volumize muscles. Clinically, insulin isn’t prescribed for muscle growth (except indirectly in managing diabetes to prevent muscle wasting). The evidence of insulin’s anabolic effect is strong in principle (it’s well known to decrease muscle protein breakdown), but in practice insulin’s contribution to extra muscle gains (beyond what can be achieved with ample food and normal hormone levels) is debated among athletes.
- Creatine (OTC Supplement): Not a medication per se, but worth mentioning as an OTC substance that does enhance strength and muscle mass. Creatine increases muscle phosphocreatine stores, improving high-power exercise performance, and it causes cellular water retention in muscle, leading to quick size gains. Over months, creatine users gain more lean mass (due to training harder and cell volumization). It’s one of the most evidence-backed supplements for muscle, with strong evidence for improved strength and modest hypertrophy. Again, it’s not a “drug” by regulatory standards, but it influences muscle gains positively.
- Myostatin Inhibitors: Myostatin is a protein that limits muscle growth. Experimental drugs (like follistatin gene therapy or myostatin-neutralizing antibodies) can cause substantial muscle mass increases (seen in animal models and initial human trials for muscular dystrophy). These aren’t on the market for general use, but future medications that inhibit myostatin or related pathways could be powerful muscle builders. At present, though, none are widely available due to safety/efficacy issues in trials (some caused bleeding risk or didn’t improve function as hoped).
- Hormone Replacement in Deficiency: Treating an underlying hormone deficiency can enhance muscle. For example, Testosterone Replacement Therapy (TRT) in hypogonadal men leads to increased muscle mass and strength (on a smaller scale than supra-physiologic steroid abuse, but significant compared to before therapy). Similarly, Growth Hormone replacement in GH-deficient adults improves muscle mass and exercise capacity. Even estrogen replacement in postmenopausal women can help maintain muscle and bone (lack of estrogen is associated with frailty). These medical therapies essentially restore normal muscle development capacity rather than push it beyond normal.
- Ephedrine/Pseudoephedrine and Caffeine: These stimulants (the former was in some OTC diet pills) can acutely improve workout performance via adrenaline release. Ephedrine, which has some beta-agonist properties, was shown to increase strength endurance and aid fat loss, indirectly benefiting muscle definition. Chronic use, however, has risks and their muscle-building capacity is mostly indirect (allowing more intense training).
- Branched-Chain Amino Acids / Protein Supplements: Again not “medications”, but high-quality protein or amino acid supplements ensure the building blocks for muscle are abundant, thereby enhancing recovery and hypertrophy. They are a nutritional foundation for muscle gain.
Summary Tables
Medications that May Impair Muscle Mass/Strength Gains
| Drug Class | Example Medications | Effect on Muscle Mass | Effect on Muscle Strength | Acute vs. Chronic Use Impact | Strength of Evidence |
|---|---|---|---|---|---|
| Glucocorticoids (Corticosteroids) | Prednisone, Dexamethasone | Decreases muscle mass (catabolic). Causes muscle protein breakdown and atrophy, especially of fast-twitch fibers. | Decreases strength via muscle wasting and fiber atrophy. Notable proximal weakness with prolonged use. | Acute: Short bursts have minimal lasting atrophy (transient weakness possible at high dose). Chronic: Long-term use causes significant muscle wasting and weakness. | Strong: Well-documented clinical and experimental evidence of steroid myopathy and catabolic effects on muscle. |
| Statins (Cholesterol-lowering) | Simvastatin, Atorvastatin | May slightly decrease muscle mass in susceptible individuals. Can cause muscle fiber damage in rare cases (rhabdo). Generally, mass loss is mild but possible via mitochondrial impairment and reduced protein synthesis signaling. | May decrease performance and slight strength gains. Causes muscle pain/weakness in some, which can limit training intensity. Large strength deficits are not typical, but statin users might gain strength more slowly. | Acute: Initial weeks can cause myalgia and fatigue, hindering workouts; pain often subsides after a few weeks. Chronic: Ongoing use can blunt training adaptations (e.g. reduced improvement in endurance and possibly strength). Effects are subtle for most, but significant in a subset. | Moderate: Some RCT evidence of blunted exercise gains; widespread anecdotal reports of muscle issues. Mechanistic support via CoQ10 depletion and myopathic side effects. |
| Selective Serotonin Reuptake Inhibitors (SSRIs) | Fluoxetine, Sertraline, Citalopram | Potentially decreases or limits muscle mass gain. Chronic SSRI use linked to reduced muscle fiber size in animal studies. May promote insulin resistance, hindering muscle anabolism. Weight gain on SSRIs is usually fat, not muscle. | Potentially decreases strength or functional performance. Some SSRI users exhibit lower grip strength and overall physical function (especially older adults). Can cause fatigue and neuromuscular side effects (tremor, stiffness) that reduce training quality. | Acute: Little direct effect on muscle; may cause lethargy or tremors that acutely impair exercise performance. Chronic: Metabolic and hormonal changes (e.g. slight testosterone suppression, insulin resistance) can gradually impair muscle growth/strength gains. Effects emerge over months of therapy. | Limited: Indications from preclinical studies (structural and metabolic muscle changes) and epidemiological data. Few direct exercise studies; more research needed. |
| Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) | Ibuprofen, Naproxen, High-dose Aspirin | Blunts increases in muscle mass with training when used in high doses chronically. High-dose NSAIDs block prostaglandin-mediated hypertrophy signaling, attenuating muscle fiber growth. | Blunts increases in strength gains if used daily. Strength improvements from training are smaller with chronic NSAID use (as shown in young adults on ibuprofen vs placebo). Short-term strength may actually feel improved due to pain reduction, but long-term adaptations suffer. | Acute: Occasional use has minimal impact on muscle gains; may help reduce pain to allow a workout (trade-off: slight acute synthesis reduction). Chronic: Daily/High-dose use significantly impairs hypertrophy and strength over weeks. Young trainees lost ~50% of potential muscle gains with 8 weeks of ibuprofen vs control. | Strong (in young people): RCTs show clear attenuation of hypertrophy/strength. Mixed in older adults (some studies show no harm or slight benefit). Mechanism well supported. |
| β-Blockers (Beta-Adrenergic Blockers) | Propranolol, Metoprolol, Atenolol | Neutral to slight decrease in muscle mass. No direct catabolic effect, but by limiting exercise intensity, they may indirectly result in less muscle gained from training. Muscle fiber shifts toward endurance characteristics possible (no hypertrophy advantage). | Decreases peak strength output and endurance. Lowers maximal exercise capacity and heart rate, making high-intensity training difficult. Users may experience quicker fatigue and ~10–15% lower work capacity, translating to smaller strength gains. | Acute: Immediately limits exercise performance every dose (heart can’t beat as fast) – workouts feel harder and are less productive. Chronic: Long-term training on β-blockers yields less improvement, as one is continually training below full capacity. Some adaptation occurs, but ceiling remains lowered. | Moderate (for performance): Well-known effect on aerobic capacity; logical extension to resistance training. Few direct studies on muscle hypertrophy, but performance limitation is documented. Anecdotal reports of reduced strength stamina. |
| Metformin (Biguanide) | Metformin (Glucophage) | Decreases muscle mass gains in responders. In older adults, metformin users gained significantly less lean mass from exercise vs non-users. Mechanistically, activates AMPK which inhibits some muscle growth pathways. | May slightly decrease strength gains. Trend toward blunted strength improvement noted in studies (not always significant). Muscle quality per se is not harmed, but absolute gains are smaller if muscle mass is less. | Acute: Little immediate effect on a single workout (aside from potential GI discomfort or mild fatigue in some). Chronic: Over weeks, continuous use blunts hypertrophic signaling (mTOR) and reduces cumulative muscle gain from training. Effect seen after ~3+ months of combined use and training. | Strong (in older adults): RCT evidence of reduced training-induced hypertrophy. Mechanistic rationale via AMPK/mTOR. Unknown in young athletes (likely similar trend). |
| Chronic Opioids (Analgesics) | Oxycodone, Morphine (long-term use) | Decreases muscle mass indirectly. Opioid-induced testosterone deficiency leads to loss of lean mass over time. Also promotes sedentary behavior and muscle disuse. | Decreases strength/functional capacity. Causes fatigue, and low hormone levels reduce muscle function. Users often have reduced exercise tolerance and frailty with long-term use. | Acute: Sedation and analgesia can acutely reduce coordination and cause one to overlook pain, risking injury. Chronic: Endocrine disturbances (hypogonadism) develop, leading to muscle atrophy and reduced strength over months. | Moderate: Well-known medical phenomenon of opioid-induced hypogonadism and associated muscle loss. Less direct research on exercise outcomes, but clinical observations support it. |
| Sedatives/Muscle Relaxants | Benzodiazepines (e.g. Diazepam), Zolpidem (Ambien), Carisoprodol (Soma) | Neutral to slight decrease in muscle mass (no direct effect on protein metabolism, but can reduce physical activity level). | Decreases acute performance (drowsiness, poor balance). Chronic use can indirectly reduce strength by impeding regular high-quality training (user is often lethargic or uncoordinated). | Acute: Next-day “hangover” grogginess impairs workout intensity and safety. Chronic: Persistent use leads to lower overall training volume and possibly muscle atrophy due to inactivity. Effect is behavioral more than physiological. | Limited: Primarily anecdotal/indirect evidence. Clearly, if you cannot train well, gains suffer, but no direct catabolic effect. Advice is based on known side effects (fatigue). |
| Others (e.g. Fluoroquinolone Antibiotics) | Ciprofloxacin, Levofloxacin | Neutral for muscle mass per se (no metabolic effect on muscle growth). | Can cause injury that affects strength. Raises risk of tendonitis/tendon rupture; a rupture can severely set back strength. Also causes muscle/joint pain in some, limiting training. | Acute: During the antibiotic course (usually 1–2 weeks), high-intensity exercise should be curtailed to avoid tendon injury. Minimal direct effect on muscle otherwise. Chronic: Not used chronically (effects are in acute use window). | Moderate (re: injury risk): FDA warnings exist for tendon damage. Indirect evidence that avoiding heavy training on these meds is prudent. Not about hypertrophy signaling, but about preventing catastrophic setbacks. |
Medications (and Substances) that May Enhance Muscle Mass/Strength
| Drug Class | Example Agents | Effect on Muscle Mass | Effect on Muscle Strength | Acute vs. Chronic Use | Strength of Evidence |
|---|---|---|---|---|---|
| Anabolic Androgenic Steroids | Testosterone (in supraphysiologic doses), Dianabol, Trenbolone | Greatly increases muscle mass. Stimulates muscle fiber hypertrophy and some hyperplasia; dose-dependent large gains in lean body mass. Can achieve muscle size beyond natural limits. | Greatly increases strength. Allows rapid strength gains due to larger muscles and enhanced neuromuscular function. Strength increases are proportional to mass gained, often dramatic with training. | Acute: No immediate strength boost from a single dose (apart from placebo effect); requires weeks to build tissue. Chronic/Cycles: Over 6–12+ weeks, significant muscle and strength gains accrue. Long-term cycles maintain and amplify gains (but with health risks). | Strong: Extensive clinical and illicit-use data. RCTs and studies on athletes show unequivocal large increases in muscle size and strength. |
| β₂-Adrenergic Agonists | Clenbuterol, Albuterol (high-dose), Formoterol | Increases lean muscle mass while reducing fat. Notably enlarges fast-twitch fibers; moderate hypertrophy effect (less than steroids but significant). Also causes some muscle definition via fat loss. | Increases strength moderately (via larger muscle fibers and enhanced fiber recruitment) but may reduce endurance. E.g., clenbuterol users saw ~27% strength gain vs 14% naturally, but endurance capacity fell. | Acute: Small transient strength boost from CNS stimulation; shaky hands can impair fine motor control though. Chronic: Over weeks, noticeable muscle and strength gains occur, especially when combined with training. Prolonged use yields diminishing returns due to receptor down-regulation and can degrade performance (endurance, muscle quality). | Moderate: Strong evidence in animals; in humans, some RCT and clinical data show lean mass and strength increases. Recognized doping agents. Side effects temper their use. |
| Human Growth Hormone (hGH) | Somatropin (rHGH) injections | Modestly increases lean body mass. Causes muscle cell hyperplasia and water retention in muscle, yielding ~2–4 kg lean mass gain in short term (some is fluid). Over long term, can contribute to muscle maintenance in aging or deficiency. | Minor direct increases in strength. GH alone doesn’t significantly improve strength in healthy adults short-term; any strength gain comes from increased muscle size (which may not be fully functional). In GH-deficient individuals, strength improves when deficiency corrected. | Acute: No acute boost; GH works over weeks by altering body composition. Chronic: Over months, adds lean mass and may slightly improve strength/endurance especially if combined with exercise. Often used in cycles of months. | Moderate: High-quality studies show increased lean mass without strength gain in young athletes. Clearly beneficial in GH-deficient persons. Mixed results in normal adults – measurable size increase but performance gains lacking. |
| Selective Androgen Receptor Modulators (SARMs) | Ostarine (Enobosarm), LGD-4033, RAD-140 | Increases muscle mass above placebo. Dose-dependent lean mass gains (~1–3 kg over a few months at tested doses). Considered less potent than traditional steroids but still anabolic. | Increases strength modestly. Trials note improvements in physical function (e.g. stair climb, grip strength) with SARMs. In recreational use, users report strength gains, though not as extreme as AAS. | Acute: No immediate effect; requires sustained use. Chronic: Over 8–12 weeks, results become evident – more muscle, some fat loss, strength uptick. Long-term safety unknown; likely need cycling as they can suppress natural testosterone somewhat. | Moderate: Clinical trials in elderly and clinical populations show clear lean mass increases. Fewer studies than AAS, but data consistently show anabolic effects. Enthusiast usage corroborates moderate efficacy. |
| Insulin (with adequate nutrition) | Exogenous insulin (in bodybuilders), high-dose carbohydrate/insulin pairing | Increases muscle glycogen and water content (rapid weight gain) and supports anabolism by preventing protein breakdown. When combined with high caloric intake, can increase muscle mass, though much of initial gain is glycogen/water. | Can increase strength indirectly by allowing greater training volume (muscles well-fueled/recovered). Insulin’s anti-catabolic effect helps preserve strength during intense training/dieting. No direct neural boost. | Acute: Strong acute effect on nutrient uptake – if used post-workout with carbs, can enhance recovery and “pump” but also risk hypoglycemia. Chronic: Over weeks, facilitates greater muscle growth (provided diet/training are in surplus). Chronic high use leads to fat gain and needs careful cycling. | Moderate: No RCTs (unethical in healthy folk), but known physiology and anecdotal reports in bodybuilding indicate it’s anabolic. Insulin is essential for muscle maintenance (diabetics lose muscle without it). |
| Hormone Replacement (in deficient populations) | Testosterone Replacement Therapy, hGH in GH-deficient, HRT (estrogen) in menopausal women | Restores or mildly increases muscle mass back toward normal for age. TRT in hypogonadal men increases lean mass and muscle size moderately (few kg) over 6–12 months. GH in deficient adults increases muscle mass (~10% increase). | Improves strength and physical function to normal levels. E.g., TRT improves grip strength, muscle power in middle-aged men with low T. Estrogen therapy can reduce post-menopausal muscle loss (indirectly helping strength). | Acute: Not applicable – hormonal therapy works gradually. Chronic: Over months of consistent therapy, deficits are corrected and muscle/strength incrementally improve, plateauing at healthy-normal levels. | Strong (for deficits): Many clinical studies show significant muscle/strength improvements when correcting hormone deficiencies. This is standard care for hypogonadism/GH deficiency. |
| Creatine (Supplement) | Creatine monohydrate (OTC supplement) | Increases muscle mass by ~1–2 kg in first weeks (mostly water into muscle cells), and greater long-term gains via improved training capacity. Promotes higher training volume leading to more hypertrophy. | Increases strength/power significantly. Allows extra reps or weight by boosting ATP availability. Consistently improves performance in short-duration high-intensity exercise, translating to larger strength gains over time. | Acute: Within days, muscles volumize (water uptake) and slight performance boost in heavy lifts. Chronic: Allows greater progressive overload, so over months users gain more strength and size than non-users. Must be taken continuously to maintain effect. | Strong: Hundreds of studies support creatine’s ergogenic and hypertrophic benefits. It is one of the most evidence-backed aids for muscle/strength. (Though not a “medication,” its effect is relevant.) |
| Others (Myostatin inhibitors, etc.) | Experimental myostatin antibodies (e.g. trevogrumab) – not yet approved | Dramatically increases muscle mass in theory (by removing growth limits). Animal knockout of myostatin doubles muscle mass. Early trials in humans with muscle diseases showed increased muscle volume but results variable. | Potentially increases strength if functional muscle added. However, some trials showed size increase without proportional strength (muscle quality issues). More data needed. | Acute: N/A (these are long-term biological changes). Chronic: Would progressively increase muscle beyond normal, as muscle stem cells proliferate without myostatin’s brake. Effects likely seen over months. | Limited (in humans): Strong genetic/animal evidence; human trials ongoing. Not available clinically for general use yet. Possibly a future therapeutic class for sarcopenia or cachexia. |
Conclusion
Medications can have profound effects on the outcomes of resistance training. Catabolic or interfering drugs – like chronic corticosteroids, high-dose NSAIDs, certain cholesterol, and antidepressant medications – may hamper muscle protein synthesis, enhance protein breakdown, or reduce one’s ability to train hard, thereby limiting muscle size and strength gains. Often, these effects are more pronounced with long-term use and at higher dosages, whereas short-term or occasional use has minor impact (with some exceptions like beta-blockers which act immediately each use). On the other hand, anabolic or enhancing drugs – such as androgens, certain metabolic or hormonal agents, and experimental compounds – can significantly boost muscle hypertrophy and strength, either by creating a more anabolic internal environment or by enabling more intense training and recovery. These tend to exert effects over weeks to months, with larger gains accumulating with sustained use (though often with accompanying risks and side effects).In applying this knowledge, one must balance medical necessity with fitness goals. If a medication that impairs muscle gains is medically required, strategies can mitigate its impact (for example, a statin user might supplement CoQ10 to support muscle mitochondria, or a lifter on beta-blockers can use perceived exertion to guide training intensity since heart rate is blunted). Conversely, pursuing muscle enhancement via drugs should be approached with caution due to health ramifications; the most extreme gains (as seen with anabolic steroids) come with significant long-term risks.
Ultimately, understanding how these drugs work empowers individuals and clinicians to make informed decisions. Adjusting training programs, nutrition, or medication timing can help optimize muscle outcomes. For instance, avoiding chronic NSAID use around workouts or incorporating resistance exercise to counter glucocorticoid myopathy can preserve muscle. As research evolves – such as ongoing studies on metformin’s role in exercise or development of SARMs for frailty – we will better navigate the interaction between medications and the body’s ability to grow stronger. In summary, medications have a spectrum of effects from muscle-breaking to muscle-building, and recognizing where a given drug lies on that spectrum is key to managing and maximizing one’s resistance training progress.
Last edited:
